Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Emergent BioSolutions Inc. operates as a global specialty biopharmaceutical company. The Company develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Emergent BioSolutions also develops and commercializes therapeutics and other specialty products for hospitals and clinics.
Website: emergentbiosolutions.com



Growth: Bad revenue growth rate -44.7%, there is slowdown compared to average historical growth rates -10.6%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -29.3%

Profitability: LTM EBITDA margin is positive, +24.4%. On average the margin is improving steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.93 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 89.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 489.0% higher than minimum and 58.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.6x by EV / Sales multiple , the company can be 63.9% undervalued

Insiders: For the last 3 months insiders sold company shares on $0.1 mln (-0.030% of cap.)

Key Financials (Download financials)

Ticker: EBS
Share price, USD:  (-1.2%)8.835
year average price 7.77  


year start price 8.47 2024-10-01

max close price 11.97 2024-11-11

min close price 4.26 2025-04-10

current price 8.84 2025-09-30
Common stocks: 50 243 601

Dividend Yield:  0.0%
FCF Yield LTM: 89.2%
EV / LTM EBITDA: 4.1x
EV / EBITDA annualized: 8.5x
EV / Sales: 1.0x
Margin (EBITDA LTM / Revenue): 24.4%
Fundamental value created in LTM:
Market Cap ($m): 444
Net Debt ($m): 401
EV (Enterprise Value): 845
Price to Book: 0.9x
Latest review:

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-09-19globenewswire.com

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

2025-09-15globenewswire.com

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

2025-09-02globenewswire.com

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

2025-08-29globenewswire.com

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

2025-08-12seekingalpha.com

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

2025-08-07seekingalpha.com

Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

2025-07-28globenewswire.com

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

2025-07-08globenewswire.com

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

2025-07-02globenewswire.com

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

2025-06-25globenewswire.com

ABeam Consulting (USA) Ltd. and Millennium EBS Establish Strategic Collaborations to Expedite ISO 20022 Implementation
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EBS EBS EBS EBS EBS EBS EBS EBS EBS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-07 2024-03-31 2024-03-08 2023-12-11 2023-08-09 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-11-06 17:46:15 2024-08-06 17:37:18 2024-03-30 20:00:00 2024-03-08 16:21:44 2023-12-11 07:24:51 2023-08-08 18:42:41 2023-05-09 17:51:12 2023-03-01 16:18:41 2022-11-08 18:19:51
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 270M 255M 300M 277M 271M 338M 165M 331M 240M
costOfRevenue 0 309M 161M 202M 177M 191M 155M 219M 149M
grossProfit 270M -55M 139M 75M 94M 147M 10M 111M 91M
grossProfitRatio 1 -0.214 0.464 0.27 0.346 0.436 0.061 0.337 0.381
researchAndDevelopmentExpenses 14M 27M 15M 29M 15M 26M 41M 58M 39M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 77M 77M 85M 88M 86M 91M 101M 94M 80M
otherExpenses 139M -3M -3M 11M -3M -4M 17M 18M 14M
operatingExpenses 229M 105M 100M 117M 118M 134M 158M 170M 133M
costAndExpenses 229M 414M 261M 319M 294M 324M 313M 389M 282M
interestIncome 0 0 0 0 0 29M 0 0 0
interestExpense 8M 24M 24M 22M 20M 29M 18M 13M 9M
depreciationAndAmortization 26M 29M 29M 31M 16M 33M 40M 42M 19M
ebitda 65M -217M 69M -11M -11M 43M -109M -16M -23M
ebitdaratio 0.239 -0.509 0.228 -0.041 -0.041 0.128 -0.658 -0.049 -0.096
operatingIncome 65M -159M 40M -42M -242M -293M -148M -58M -42M
operatingIncomeRatio 0.239 -0.625 0.132 -0.151 -0.895 -0.867 -0.897 -0.177 -0.175
totalOtherIncomeExpensesNet 78M -111M -28M -13M -222M -235M -13M -13M -22M
incomeBeforeTax 142M -270M 12M -55M -266M -250M -161M -71M -64M
incomeBeforeTaxRatio 0.528 -1.059 0.04 -0.197 -0.983 -0.74 -0.976 -0.215 -0.266
incomeTaxExpense 28M 13M 3M -5M 16M 11M 22M 17M 12M
netIncome 115M -283M 9M -50M -266M -261M -183M -88M -76M
netIncomeRatio 0.426 -1.112 0.03 -0.179 -0.983 -0.773 -1.108 -0.266 -0.315
eps 2.16 -5.38 0.17 -0.95 -5.13 -5.15 -3.65 -1.76 -1.52
epsdiluted 2.06 -5.38 0.17 -0.95 -5.13 -5.15 -3.65 -1.76 -1.52
weightedAverageShsOut 53M 53M 52M 52M 52M 51M 50M 50M 50M
weightedAverageShsOutDil 56M 53M 52M 52M 52M 51M 50M 50M 50M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EBS EBS EBS EBS EBS EBS EBS EBS EBS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-07 2024-03-31 2024-03-08 2023-12-11 2023-08-09 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-11-06 17:46:15 2024-08-06 17:37:18 2024-03-30 20:00:00 2024-03-08 16:21:44 2023-12-11 07:24:51 2023-08-08 18:42:41 2023-05-09 17:51:12 2023-03-01 16:18:41 2022-11-08 18:19:51
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 150M 71M 79M 112M 88M 89M 430M 643M 241M
shortTermInvestments 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 150M 71M 79M 112M 88M 89M 430M 643M 241M
netReceivables 121M 196M 234M 191M 217M 290M 156M 158M 191M
inventory 323M 318M 333M 329M 354M 354M 368M 352M 546M
otherCurrentAssets 68M 71M 37M 48M 62M 45M 267M 58M 140M
totalCurrentAssets 661M 655M 682M 680M 354M 778M 1 221M 1 211M 1 119M
propertyPlantEquipmentNet 278M 320M 395M 399M 395M 396M 717M 818M 807M
goodwill 1 0 0 0 0 218M 218M 218M 225M
intangibleAssets 518M 534M 550M 567M 583M 593M 609M 729M 723M
goodwillAndIntangibleAssets 518M 534M 550M 567M 583M 811M 827M 947M 948M
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 12M 0 0 0 0 0
otherNonCurrentAssets 21M 5M 176M 178M 194M 195M 185M 191M 36M
totalNonCurrentAssets 816M 859M 1 121M 1 155M 1 172M 1 401M 1 729M 1 956M 1 790M
otherAssets 0 0 1 0 367M 0 0 0 0
totalAssets 1 478M 1 514M 1 804M 1 835M 1 893M 2 179M 2 950M 3 167M 2 909M
accountPayables 82M 96M 100M 112M 113M 108M 124M 104M 104M
shortTermDebt 800 000 415M 463M 417M 414M 455M 951M 957M 21M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 6M 6M 27M 23M 101M 0 0 0
otherCurrentLiabilities 147M 109M 62M 95M 115M 29M 141M 169M 143M
totalCurrentLiabilities 230M 620M 630M 651M 664M 693M 1 216M 1 230M 268M
longTermDebt 0 459M 447M 447M 448M 448M 448M 449M 1 032M
deferredRevenueNonCurrent 0 12M 13M 14M -448M 0 0 0 0
deferredTaxLiabilitiesNonCurrent 42M 35M 35M 59M 52M 58M 60M 72M 114M
otherNonCurrentLiabilities 698M 14M 15M 15M 480M 23M 24M 33M 1 066M
totalNonCurrentLiabilities 740M 508M 510M 534M 532M 529M 532M 554M 1 191M
otherLiabilities 0 0 0 1 0 0 0 0 0
capitalLeaseObligations 0 12M 13M 14M 15M 13M 0 0 0
totalLiabilities 969M 1 127M 1 140M 1 186M 1 196M 1 223M 1 747M 1 784M 1 459M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000 100 000
retainedEarnings -181M -296M -13M -22M 28M 290M 551M 734M 822M
accumulatedOtherComprehensiveIncomeLoss -7M -6M -6M -6M -3M -2M 1 000 000 3M -5M
othertotalStockholdersEquity 697M 688M 682M 677M 672M 668M 651M 646M 632M
totalStockholdersEquity 508M 386M 664M 649M 697M 956M 1 203M 1 383M 1 449M
totalEquity 508M 386M 664M 649M 697M 956M 1 203M 1 383M 1 449M
totalLiabilitiesAndStockholdersEquity 1 478M 1 514M 1 804M 1 835M 1 893M 2 179M 2 950M 3 167M 2 909M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 478M 1 514M 1 804M 1 835M 1 893M 2 179M 2 950M 3 167M 2 909M
totalInvestments 0 0 0 0 0 0 0 0 0
totalDebt 800 000 877M 922M 878M 414M 903M 1 398M 1 406M 1 053M
netDebt -149M 806M 843M 766M 326M 815M 968M 763M 812M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol EBS EBS EBS EBS EBS EBS EBS EBS EBS
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-07 2024-03-31 2024-03-08 2023-12-11 2023-08-09 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-11-06 17:46:15 2024-08-06 17:37:18 2024-03-30 20:00:00 2024-03-08 16:21:44 2023-12-11 07:24:51 2023-08-08 18:42:41 2023-05-09 17:51:12 2023-03-01 16:18:41 2022-11-08 18:19:51
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 115M -283M 9M -50M -263M -261M -183M -88M -76M
depreciationAndAmortization 26M 29M 29M 31M 29M 33M 35M 36M 32M
deferredIncomeTax 7M -200 000 -12M -5M 7M -2M -8M -42M 20M
stockBasedCompensation 2M 6M 6M 4M 4M 8M 7M 12M 11M
changeInWorkingCapital 66M 206M -98M 47M 65M -145M -37M 174M -75M
accountsReceivables 82M 20M -50M 37M 72M -132M 2M 39M -22M
inventory -18M -13M -5M 26M -1M 6M -30M 60M -37M
accountsPayables -23M 3M -2M -7M 7M -20M 31M -5M -1M
otherWorkingCapital 24M 196M -41M -9M -13M 2M -40M 80M -15M
otherNonCashItems -63M 144M 124M 6M 219M 253M 3M 1M 13M
netCashProvidedByOperatingActivities 154M 48M -63M 32M 60M -114M -184M 93M -74M
investmentsInPropertyPlantAndEquipment -6M -5M -11M -11M -13M -13M -15M -24M -28M
acquisitionsNet 0 0 0 -270M 0 270M 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0
otherInvestingActivites 118M 0 0 270M -6M 0 0 -22M -244M
netCashUsedForInvestingActivites 112M -5M -11M -11M -19M 258M -15M -45M -272M
debtRepayment -194M -51M -41M -4M -43M -496M -8M -9M -8M
commonStockIssued 9M 700 000 0 700 000 0 10M 0 0 0
commonStockRepurchased 0 -200 000 -400 000 -100 000 -100 000 -200 000 0 -200 000 0
dividendsPaid 0 0 0 0 0 -9M 0 0 0
otherFinancingActivites 4M 500 000 -400 000 8M -100 000 9M -2M 362M 238M
netCashUsedProvidedByFinancingActivities -180M -51M 41M 5M -43M -487M -11M 353M 229M
effectOfForexChangesOnCash 0 0 0 -2M 1M -600 000 -200 000 1M -1 000 000
netChangeInCash 85M -8M -33M 24M -91M -342M -212M 402M -117M
cashAtEndOfPeriod 156M 71M 79M 112M -2M 89M 430M 643M 241M
cashAtBeginningOfPeriod 71M 79M 112M 88M 89M 430M 643M 241M 358M
operatingCashFlow 154M 48M -63M 32M 60M -114M -184M 93M -74M
capitalExpenditure -6M -5M -11M -11M -13M -13M -15M -24M -28M
freeCashFlow 148M 43M -73M 21M 47M -127M -199M 69M -102M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-03-06 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-27 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-01 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-06 21:49 ET
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
2024-11-06 21:05 ET
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
2024-11-04 12:30 ET
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
2024-10-23 11:30 ET
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
2024-10-08 21:32 ET
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
2024-10-02 11:30 ET
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
2024-09-26 12:05 ET
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
2024-09-25 11:07 ET
Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts
2024-09-13 10:45 ET
Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
2024-09-12 12:30 ET
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
2024-09-03 11:08 ET
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
2024-08-30 12:16 ET
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
2024-08-06 12:00 ET
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
2024-07-31 12:53 ET
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
2024-07-24 11:30 ET
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
2024-07-23 12:27 ET
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
2024-07-09 11:30 ET
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
2024-07-02 12:13 ET
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
2024-06-20 11:00 ET
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
2024-06-06 13:02 ET
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
2024-05-10 11:17 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
2024-05-01 20:57 ET
Emergent BioSolutions Reports First Quarter 2024 Financial Results
2024-05-01 20:10 ET
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
2024-05-01 15:03 ET
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
2024-04-30 21:26 ET
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
2024-04-22 12:05 ET
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
2024-03-28 12:15 ET
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
2024-03-25 12:05 ET
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
2024-03-06 21:31 ET
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
2024-02-29 12:00 ET
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
2024-02-21 12:00 ET
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
2024-01-11 13:00 ET
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
2024-01-09 12:30 ET
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
2023-11-28 11:59 ET
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
2023-11-24 12:30 ET
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
2023-11-08 22:38 ET
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
2023-10-30 20:45 ET
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
2023-10-19 10:30 ET
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
2023-10-16 11:00 ET
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
2023-10-02 11:00 ET
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
2023-08-30 09:59 ET
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
2023-08-08 20:31 ET
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
2023-08-08 11:15 ET
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
2023-07-31 20:05 ET
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
2023-07-25 10:30 ET
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
2023-07-20 22:03 ET
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
2023-06-27 11:55 ET
Emergent BioSolutions Announces CEO Transition
2023-05-15 11:58 ET
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
2023-05-15 11:58 ET
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
2023-05-11 10:30 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
2023-05-09 20:05 ET
Emergent BioSolutions Reports Financial Results For First Quarter 2023
2023-04-19 20:05 ET
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
2023-03-29 13:48 ET
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
2023-02-27 21:42 ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
2023-02-15 22:19 ET
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
2023-02-15 07:00 ET
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
2023-02-15 07:00 ET
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
2023-02-06 21:05 ET
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
2023-01-09 11:59 ET
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
2023-01-05 22:30 ET
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
2022-12-06 11:00 ET
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
2022-11-14 11:30 ET
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
2022-11-08 21:16 ET
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
2022-11-01 20:05 ET
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
2022-10-27 12:30 ET
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
2022-10-18 10:30 ET
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
2022-09-26 20:12 ET
Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
2022-09-06 10:30 ET
Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate
2022-08-10 10:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2022-08-01 20:05 ET
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
2022-07-18 20:05 ET
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022
2022-07-07 20:30 ET
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
2022-07-06 20:05 ET
Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors
2022-06-24 10:30 ET
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
2022-06-21 10:30 ET
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
2022-06-02 12:20 ET
Emergent BioSolutions to Participate in Investor Conferences
2022-05-16 10:32 ET
Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
2022-05-12 10:30 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
2022-05-10 20:42 ET
SHAREHOLDER ALERT: Weiss Law Investigates Emergent BioSolutions Inc.
2022-04-28 20:05 ET
Emergent BioSolutions Reports Financial Results For First Quarter 2022
2022-04-08 10:30 ET
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
2022-03-23 20:05 ET
Emergent BioSolutions Provides Corporate Governance Update
2022-03-14 20:05 ET
Emergent BioSolutions to Participate in Investor Conferences
2022-03-11 11:34 ET
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
2022-02-24 21:05 ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
2022-02-07 11:30 ET
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
2022-01-14 11:30 ET
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
2022-01-09 19:00 ET
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
2022-01-03 11:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2021-12-16 12:30 ET
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
2021-11-22 23:01 ET
SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap 600
2021-11-11 21:05 ET
Emergent BioSolutions Announces Stock Repurchase Program
2021-11-04 20:05 ET
Emergent BioSolutions Reports Financial Results For Third Quarter 2021
2021-10-18 10:30 ET
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
2021-10-15 10:30 ET
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
2021-09-21 17:23 ET
Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.
2021-09-14 12:00 ET
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
2021-08-25 10:30 ET
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
2021-08-23 20:05 ET
Emergent BioSolutions to Participate in Investor Conferences
2021-07-29 20:05 ET
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
2021-07-29 11:24 ET
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
2021-07-26 13:01 ET
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
2021-07-15 10:30 ET
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
2021-06-11 20:35 ET
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
2021-05-26 10:30 ET
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
2021-05-06 10:30 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
2021-05-05 20:05 ET
Emergent BioSolutions to Participate in Investor Conferences
2021-04-29 20:05 ET
Emergent BioSolutions Reports Financial Results for First Quarter 2021
2021-04-21 16:46 ET
Statement on Issuance of Form FDA 483 at Emergent Bayview Facility
2021-04-15 10:30 ET
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
2021-04-08 15:51 ET
Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS)
2021-04-02 12:00 ET
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
2021-03-01 11:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2021-02-18 21:05 ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
2021-02-04 11:30 ET
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
2021-01-10 19:00 ET
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
2021-01-04 11:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2020-12-29 21:05 ET
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
2020-11-05 21:05 ET
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
2020-10-15 10:30 ET
Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
2020-10-08 20:05 ET
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
2020-08-31 10:30 ET
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
2020-08-26 10:30 ET
Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
2020-08-18 10:31 ET
Emergent BioSolutions to Participate in Virtual Investor Conferences
2020-08-17 10:30 ET
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
2020-08-07 20:05 ET
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
2020-08-04 22:31 ET
Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
2020-08-04 12:00 ET
Emergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured Notes
2020-07-30 20:27 ET
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
2020-07-27 10:30 ET
Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate
2020-07-21 20:45 ET
Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index
2020-07-20 22:36 ET
Emergent BioSolutions Set to Join S&P MidCap 400; First Hawaiian to Join S&P SmallCap 600
2020-07-16 10:30 ET
Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
2020-07-08 13:00 ET
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
2020-07-06 10:30 ET
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate   
2020-06-18 10:30 ET
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
2020-06-16 20:05 ET
Emergent BioSolutions to Participate in Virtual Investor Conferences
2020-06-11 12:47 ET
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate
2020-06-05 23:39 ET
Emergent BioSolutions Statement on U.S. District Court Decision
2020-06-01 10:30 ET
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
2020-05-12 10:00 ET
Emergent BioSolutions to Participate in Virtual Investor Conferences
2020-05-07 13:20 ET
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT
2020-04-30 20:08 ET
Emergent BioSolutions Reports Financial Results for First Quarter 2020
2020-04-23 22:51 ET
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
2020-04-21 20:55 ET
Emergent BioSolutions Appoints Dr. Karen L. Smith as Chief Medical Officer
2020-04-16 10:30 ET
Emergent BioSolutions to Release First Quarter 2020 Financial Results and Conduct Conference Call on April 30, 2020
2020-04-06 10:30 ET
Emergent BioSolutions Appoints Nina DeLorenzo as Senior Vice President of Global Public Affairs
2020-04-02 20:05 ET
Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19
2020-03-31 20:05 ET
Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
2020-03-18 10:30 ET
EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
2020-03-11 20:21 ET
Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease
2020-03-10 09:30 ET
Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
2020-02-20 21:31 ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019
2020-02-03 21:30 ET
Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
2020-01-31 14:26 ET
Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
2020-01-13 11:40 ET
Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
2020-01-13 11:30 ET
Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
2020-01-06 11:30 ET
Emergent BioSolutions to Participate in Investor Conferences
2019-12-20 18:00 ET
Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
2019-11-22 13:19 ET
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
2019-11-21 21:05 ET
Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
2019-11-18 11:30 ET
Emergent BioSolutions to Host 2019 Analyst and Investor Day
2019-11-06 21:05 ET
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
2019-04-18 11:22 ET
Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
2019-04-16 10:30 ET
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
2019-03-19 10:30 ET
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax

SEC forms

Show financial reports only

SEC form 10
2025-08-06 21:50 ET
Emergent BioSolutions reported for 2025 q2
SEC form 8
2025-08-06 20:13 ET
Emergent BioSolutions published news for 2025 q2
SEC form 8
2025-08-06 20:13 ET
Emergent BioSolutions reported for 2025 q2
SEC form 8
2025-08-06 20:13 ET
Emergent BioSolutions published news for 2025 q2
SEC form 8
2025-06-24 20:09 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-06-24 20:09 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-23 20:06 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-23 20:06 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-23 20:06 ET
Emergent BioSolutions published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Emergent BioSolutions published news for 2025 q1
SEC form 10
2025-05-07 21:46 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-07 20:08 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-07 20:08 ET
Emergent BioSolutions reported for 2025 q1
SEC form 8
2025-05-07 20:08 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-05-06 20:19 ET
Emergent BioSolutions published news for 2025 q1
SEC form 8
2025-03-31 12:06 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-31 12:06 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-10 20:47 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-10 20:47 ET
Emergent BioSolutions published news for 2024 q4
SEC form 10
2025-03-04 00:00 ET
Emergent BioSolutions published news for 2024 q4
SEC form 10
2025-03-03 22:41 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-03 16:27 ET
Emergent BioSolutions published news for 2024 q4
SEC form 8
2025-03-03 16:27 ET
Emergent BioSolutions reported for 2024 q4
SEC form 8
2025-03-03 16:27 ET
Emergent BioSolutions published news for 2024 q4
SEC form 10
2024-11-06 17:46 ET
Emergent BioSolutions published news for 2024 q3
SEC form 8
2024-11-06 16:12 ET
Emergent BioSolutions published news for 2024 q3
SEC form 8
2024-11-06 16:12 ET
Emergent BioSolutions published news for 2024 q3
SEC form 8
2024-11-06 16:12 ET
Emergent BioSolutions published news for 2024 q3
SEC form 10
2024-08-07 00:00 ET
Emergent BioSolutions published news for 2024 q2
SEC form 10
2024-08-06 17:37 ET
Emergent BioSolutions published news for 2024 q2
SEC form 8
2024-08-06 16:21 ET
Emergent BioSolutions published news for 2024 q2
SEC form 8
2024-08-06 16:21 ET
Emergent BioSolutions reported for 2024 q2
SEC form 8
2024-08-06 16:21 ET
Emergent BioSolutions published news for 2024 q2
SEC form 10
2024-05-02 00:00 ET
Emergent BioSolutions published news for 2024 q1
SEC form 10
2024-05-01 17:38 ET
Emergent BioSolutions published news for 2024 q1
SEC form 10
2024-03-08 16:21 ET
Emergent BioSolutions published news for 2023 q4
SEC form 10
2024-03-08 00:00 ET
Emergent BioSolutions reported for 2023 q4
SEC form 10
2023-12-11 00:00 ET
Emergent BioSolutions published news for 2023 q3
SEC form 8
2023-11-08 16:21 ET
Emergent BioSolutions reported for 2023 q3
SEC form 10
2023-08-09 00:00 ET
Emergent BioSolutions reported for 2023 q2
SEC form 10
2023-08-08 18:42 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-08-08 16:12 ET
Emergent BioSolutions reported for 2023 q2
SEC form 6
2023-08-08 07:15 ET
Emergent BioSolutions published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-07-31 16:26 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-07-27 16:48 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-07-21 08:25 ET
Emergent BioSolutions published news for 2023 q2
SEC form 6
2023-06-27 07:54 ET
Emergent BioSolutions published news for 2023 q1
SEC form 6
2023-05-31 17:00 ET
Emergent BioSolutions published news for 2023 q1
SEC form 6
2023-05-30 07:32 ET
Emergent BioSolutions published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Emergent BioSolutions published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Emergent BioSolutions reported for 2023 q1
SEC form 6
2023-04-17 07:46 ET
Emergent BioSolutions published news for 2023 q1
SEC form 6
2023-03-29 09:29 ET
Emergent BioSolutions published news for 2022 q4
SEC form 6
2023-03-23 17:25 ET
Emergent BioSolutions published news for 2022 q4
SEC form 10
2023-03-01 16:18 ET
Emergent BioSolutions reported for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Emergent BioSolutions reported for 2022 q4
SEC form 6
2023-02-27 16:46 ET
Emergent BioSolutions published news for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Emergent BioSolutions reported for 2022 q4
SEC form 6
2023-02-15 07:06 ET
Emergent BioSolutions published news for 2022 q4
SEC form 6
2023-01-09 06:55 ET
Emergent BioSolutions published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Emergent BioSolutions published news for 2022 q4
SEC form 6
2023-01-05 17:27 ET
Emergent BioSolutions published news for 2022 q4
SEC form 6
2022-12-06 07:01 ET
Emergent BioSolutions published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Emergent BioSolutions reported for 2022 q3
SEC form 10
2022-11-08 18:19 ET
Emergent BioSolutions published news for 2022 q3
SEC form 6
2022-11-08 16:52 ET
Emergent BioSolutions published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Emergent BioSolutions reported for 2022 q3
SEC form 6
2022-09-26 17:05 ET
Emergent BioSolutions published news for 2022 q2
SEC form 6
2022-08-12 17:03 ET
Emergent BioSolutions published news for 2022 q2
SEC form 6
2022-08-02 18:19 ET
Emergent BioSolutions published news for 2022 q2
SEC form 10
2022-08-02 00:00 ET
Emergent BioSolutions reported for 2022 q2
SEC form 10
2022-08-01 18:02 ET
Emergent BioSolutions published news for 2022 q2
SEC form 6
2022-08-01 16:11 ET
Emergent BioSolutions published news for 2022 q2
SEC form 8
2022-08-01 00:00 ET
Emergent BioSolutions reported for 2022 q2
SEC form 6
2022-07-06 16:09 ET
Emergent BioSolutions published news for 2022 q2
SEC form 6
2022-06-07 06:43 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-06-06 08:03 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-05-27 08:29 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-05-18 17:13 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-05-16 06:49 ET
Emergent BioSolutions published news for 2022 q1
SEC form 10
2022-04-29 00:00 ET
Emergent BioSolutions reported for 2022 q1
SEC form 10
2022-04-28 17:44 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-04-28 16:45 ET
Emergent BioSolutions published news for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Emergent BioSolutions reported for 2022 q1
SEC form 6
2022-04-15 16:51 ET
Emergent BioSolutions published news for 2022 q1
SEC form 6
2022-03-23 16:30 ET
Emergent BioSolutions published news for 2021 q4
SEC form 10
2022-02-25 16:35 ET
Emergent BioSolutions published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2022-02-24 16:22 ET
Emergent BioSolutions published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2022-02-22 16:11 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2022-01-14 06:37 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2022-01-10 06:09 ET
Emergent BioSolutions published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Emergent BioSolutions published news for 2021 q4
SEC form 6
2021-11-12 08:48 ET
Emergent BioSolutions published news for 2021 q3
SEC form 10
2021-11-05 16:51 ET
Emergent BioSolutions published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Emergent BioSolutions published news for 2021 q3
SEC form 6
2021-11-04 16:19 ET
Emergent BioSolutions published news for 2021 q3
SEC form 6
2021-11-04 16:13 ET
Emergent BioSolutions published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Emergent BioSolutions published news for 2021 q3
SEC form 6
2021-09-30 20:14 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-09-09 16:33 ET
Emergent BioSolutions published news for 2021 q2
SEC form 10
2021-07-30 00:00 ET
Emergent BioSolutions published news for 2021 q2
SEC form 10
2021-07-29 19:08 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-07-29 16:26 ET
Emergent BioSolutions published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-07-22 16:50 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-07-14 06:27 ET
Emergent BioSolutions published news for 2021 q2
SEC form 6
2021-05-25 16:59 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-05-12 08:30 ET
Emergent BioSolutions published news for 2021 q1
SEC form 10
2021-04-30 00:00 ET
Emergent BioSolutions published news for 2021 q1
SEC form 10
2021-04-29 18:01 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-29 16:24 ET
Emergent BioSolutions published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-21 13:27 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-19 06:20 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-09 16:04 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-05 07:38 ET
Emergent BioSolutions published news for 2021 q1
SEC form 6
2021-04-01 17:01 ET
Emergent BioSolutions published news for 2021 q1
SEC form 10
2021-02-18 18:52 ET
Emergent BioSolutions published news for 2020 q4
SEC form 6
2021-02-18 16:46 ET
Emergent BioSolutions published news for 2020 q4
SEC form 6
2021-02-16 16:46 ET
Emergent BioSolutions published news for 2020 q4
SEC form 6
2021-01-11 06:34 ET
Emergent BioSolutions published news for 2020 q4
SEC form 10
2020-11-05 18:54 ET
Emergent BioSolutions published news for 2020 q3
SEC form 6
2020-11-05 16:43 ET
Emergent BioSolutions published news for 2020 q3